Y H Lee1, Y H Seo2, J-H Kim2, S J Choi2, J D Ji2, G G Song2. 1. Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, 02841, Seoul, Korea. lyhcgh@korea.ac.kr. 2. Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, 02841, Seoul, Korea.
Abstract
OBJECTIVE: The aim of this study was to determine whether polymorphisms in solute carrier family 2 and facilitated glucose transporter member 9 (SLC2A9) are associated with susceptibility to gout. METHODS: A meta-analysis was conducted on associations between the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 and gout susceptibility using fixed and random effects models. RESULTS: Eleven comparative studies comprising 1,472 patients and 3,269 controls from Caucasian and Asian populations were included in this meta-analysis. The meta-analysis identified a significant negative association between gout and allele 2 (minor) of the rs12510549 polymorphism in the overall population (OR = 0.641, 95 % CI = 0.540-0.761, P = 4.1 × 10-7). Stratification by ethnicity identified a significant negative association between this polymorphism and gout in Caucasians (OR = 0.647, 95 % CI = 0.542-0.771, P = 1.2 × 10-6) but not in Asians (OR = 0.515, 95 % CI = 0.214-1.236, P = 0.137). The meta-analysis showed a significant negative association between gout and allele 2 of the rs16890979 polymorphism in all study subjects (OR = 0.229, 95 % CI = 0.084-0.628, P = 0.004). Stratification by ethnicity identified a significant negative association between this polymorphism and gout in Caucasians (OR = 0.469, 95 % CI = 0.317-0.695, P = 1.6 × 10-6) and in Asians (OR = 0.192, 95 % CI = 0.072-0.513, P = 0.001). A significant negative association was found between allele 2 of the rs1014290 polymorphism and gout susceptibility in Asians (OR = 0.597, 95 % CI = 0.478-0.746, P = 5.4 × 10-6) but not in Caucasians (OR = 0.778, 95 % CI = 0.595-1.043, P = 0.095). CONCLUSIONS: This meta-analysis shows that the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 protect against the development of gout in Caucasians and/or Asians.
OBJECTIVE: The aim of this study was to determine whether polymorphisms in solute carrier family 2 and facilitated glucose transporter member 9 (SLC2A9) are associated with susceptibility to gout. METHODS: A meta-analysis was conducted on associations between the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 and gout susceptibility using fixed and random effects models. RESULTS: Eleven comparative studies comprising 1,472 patients and 3,269 controls from Caucasian and Asian populations were included in this meta-analysis. The meta-analysis identified a significant negative association between gout and allele 2 (minor) of the rs12510549 polymorphism in the overall population (OR = 0.641, 95 % CI = 0.540-0.761, P = 4.1 × 10-7). Stratification by ethnicity identified a significant negative association between this polymorphism and gout in Caucasians (OR = 0.647, 95 % CI = 0.542-0.771, P = 1.2 × 10-6) but not in Asians (OR = 0.515, 95 % CI = 0.214-1.236, P = 0.137). The meta-analysis showed a significant negative association between gout and allele 2 of the rs16890979 polymorphism in all study subjects (OR = 0.229, 95 % CI = 0.084-0.628, P = 0.004). Stratification by ethnicity identified a significant negative association between this polymorphism and gout in Caucasians (OR = 0.469, 95 % CI = 0.317-0.695, P = 1.6 × 10-6) and in Asians (OR = 0.192, 95 % CI = 0.072-0.513, P = 0.001). A significant negative association was found between allele 2 of the rs1014290 polymorphism and gout susceptibility in Asians (OR = 0.597, 95 % CI = 0.478-0.746, P = 5.4 × 10-6) but not in Caucasians (OR = 0.778, 95 % CI = 0.595-1.043, P = 0.095). CONCLUSIONS: This meta-analysis shows that the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 protect against the development of gout in Caucasians and/or Asians.
Authors: Klaus Stark; Wibke Reinhard; Katharina Neureuther; Silke Wiedmann; Kamil Sedlacek; Andrea Baessler; Marcus Fischer; Stefan Weber; Bernhard Kaess; Jeanette Erdmann; Heribert Schunkert; Christian Hengstenberg Journal: PLoS One Date: 2008-04-09 Impact factor: 3.240
Authors: Melanie Kolz; Toby Johnson; Serena Sanna; Alexander Teumer; Veronique Vitart; Markus Perola; Massimo Mangino; Eva Albrecht; Chris Wallace; Martin Farrall; Asa Johansson; Dale R Nyholt; Yurii Aulchenko; Jacques S Beckmann; Sven Bergmann; Murielle Bochud; Morris Brown; Harry Campbell; John Connell; Anna Dominiczak; Georg Homuth; Claudia Lamina; Mark I McCarthy; Thomas Meitinger; Vincent Mooser; Patricia Munroe; Matthias Nauck; John Peden; Holger Prokisch; Perttu Salo; Veikko Salomaa; Nilesh J Samani; David Schlessinger; Manuela Uda; Uwe Völker; Gérard Waeber; Dawn Waterworth; Rui Wang-Sattler; Alan F Wright; Jerzy Adamski; John B Whitfield; Ulf Gyllensten; James F Wilson; Igor Rudan; Peter Pramstaller; Hugh Watkins; Angela Doering; H-Erich Wichmann; Tim D Spector; Leena Peltonen; Henry Völzke; Ramaiah Nagaraja; Peter Vollenweider; Mark Caulfield; Thomas Illig; Christian Gieger Journal: PLoS Genet Date: 2009-06-05 Impact factor: 5.917
Authors: Anita Brandstätter; Stefan Kiechl; Barbara Kollerits; Steven C Hunt; Iris M Heid; Stefan Coassin; Johann Willeit; Ted D Adams; Thomas Illig; Paul N Hopkins; Florian Kronenberg Journal: Diabetes Care Date: 2008-05-16 Impact factor: 19.112